Gregor Diagnostics: Funding, Investors & Team (Sep 2026)
Gregor Diagnostics is a molecular diagnostics company developing a screening test technology for prostate cancer.
Gregor Diagnostics has raised $240k across 1 funding round on record, the most recent an undisclosed round of $240k announced in Nov 2025.
That round is below the $12M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Gregor Diagnostics Company Profile and Key Stats
Latest funding round on record: Nov 2025.
Gregor Diagnostics Funding Rounds
Gregor Diagnostics Founders and Leadership Team
Contact details for the Gregor Diagnostics team: 1 of 1 has an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Gregor Diagnostics Funding Compared to Other Biotechnology Startups
Gregor Diagnostics' latest round of $240k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Gregor Diagnostics in Biotechnology and Madison
Companies Similar to Gregor Diagnostics
Expedition Therapeutics is a biotechnology company that develops novel therapies for inflammatory and…
Rion Vet mission is to drive the regenerative medicine revolution.
Modulight Bio develops an optogenetic platform intended for the treatment of neurological disorders.
Nomax Therapeutics develops a healthcare technology platform to provide therapies for neurodegenerative…
Gut Brain Axis Therapeutics is a biotechnology company that offers treatment for Autism Spectrum Disorder…
iOrganBio is a pioneering cell production platform.
BlueWhale Bio is committed to advancing cell-based therapeutics through manufacturing innovation.
NILO Therapeutics is a biotechnology and therapeutics company.
AccufyDx is a Biotechnology Research firm working to change MRD analysis for early detection.Accufy…
Predicta Biosciences provides molecular diagnostics and immunotherapeutic discovery services for…
Captain T Cell is a start-up project that develops T cell-based immunotherapies for cancer patients.
Reprogenix is a groundbreaking medical technology firm
Gregor Diagnostics Funding FAQs
What does Gregor Diagnostics do?
Gregor Diagnostics is a molecular diagnostics company developing a screening test technology for prostate cancer.
How much funding has Gregor Diagnostics raised?
Gregor Diagnostics has raised $240k across 1 round on record. The most recent is an undisclosed round of $240k announced in Nov 2025.
When did Gregor Diagnostics last raise funding?
Gregor Diagnostics' most recent funding round on record is an undisclosed round of $240k, announced in Nov 2025.
Where is Gregor Diagnostics headquartered?
Gregor Diagnostics is based in Madison, United States.
How many employees does Gregor Diagnostics have?
Gregor Diagnostics is in the 11-50 employee band.
How does Gregor Diagnostics' funding compare to other Biotechnology startups?
Gregor Diagnostics' latest round of $240k is below the $12M median round size for Biotechnology companies on FundedIQ across 27 tracked companies over the last two years.
About FundedIQ's Gregor Diagnostics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Gregor Diagnostics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.